Combined PET-CT in the head and neck Part 1. Physiologic, altered physiologic, and artifactual FDG uptake

被引:109
作者
Blodgett, TM
Fukui, MB
Snyderman, CH
Branstetter, BF
McCook, BM
Townsend, DW
Meltzer, CC
机构
[1] Univ Pittsburgh, Dept Radiol, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15213 USA
[3] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA
[4] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA
[5] Allegheny Gen Hosp, Dept Radiol, Pittsburgh, PA 15212 USA
关键词
D O I
10.1148/RG.254035156
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Positron emission tomography (PET) with 2-[fluorine-18] fluoro-2-deoxy-D-glucose (FDG) has been effective for the diagnosis, staging, and restaging of malignancies of the head and neck region. However, lack of anatomic landmarks, variable physiologic uptake, and asymmetric FDG distribution in several altered physiologic states can confound image interpretation. In addition, many benign causes and several artifacts can simulate physiologic or pathologic FDG uptake in the head and neck. Combined PET - computed tomography (CT) is a unique imaging modality that permits anatomic and functional imaging on a single scanner with nearly perfect coregistration. Combined PET-CT provides information that cannot be obtained with PET or CT alone. In particular, PET-CT facilitates the interpretation of FDG uptake in the head and neck, an area that is characterized by dense and complex anatomic structures. An atlas of FDG uptake in this anatomic region was compiled on the basis of combined PET-CT findings in 11,000 patients. In general, patterns of FDG uptake were variable and often reflected patient activity during or immediately preceding the uptake phase. With the growing interest in PET-CT, interpreting radiologists and nuclear medicine physicians must be familiar with the patterns of FDG uptake in the head and neck to avoid misinterpretation or misdiagnosis. (c) RSNA, 2005.
引用
收藏
页码:897 / 912
页数:16
相关论文
共 39 条
  • [1] Antoch G, 2002, J NUCL MED, V43, P1339
  • [2] Bar-Shalom R, 2000, SEMIN NUCL MED, V30, P306
  • [3] Barrington SF, 1996, J NUCL MED, V37, P1127
  • [4] Börner AR, 1999, NUKLEARMED-NUCL MED, V38, P1
  • [5] Carney J, 2002, J NUCL MED, V43, p57P
  • [6] Cohade C, 2003, J NUCL MED, V44, P170
  • [7] Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: Potential for error in interpretation
    Cook, GJR
    Fogelman, I
    Maisey, MN
    [J]. SEMINARS IN NUCLEAR MEDICINE, 1996, 26 (04) : 308 - 314
  • [8] Dizendorf EV, 2003, J NUCL MED, V44, P24
  • [9] Application of oral contrast media in coregistered positron emission tomography-CT
    Dizendorf, EV
    Treyer, V
    von Schulthess, GK
    Hany, TF
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2002, 179 (02) : 477 - 481
  • [10] Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography
    Farber, LA
    Benard, F
    Machtay, M
    Smith, RJ
    Weber, RS
    Weinstein, GS
    Chalian, AA
    Alavi, A
    Rosenthal, DI
    [J]. LARYNGOSCOPE, 1999, 109 (06) : 970 - 975